

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5520112

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
YUANSHAN YAO	01/25/2019
BIN CHEN	03/25/2019
YUAN CHEN	03/25/2019
AO LI	03/25/2019
RAN XU	03/25/2019
ZHENSHENG HUANG	03/25/2019
DONGDONG TIAN	03/25/2019
HONGWEI LI	03/25/2019
CHENGSHUAI YANG	03/25/2019
JIAN LI	03/25/2019
SHUHUI CHEN	02/22/2019
RECEIVING PARTY DATA	
Name:	CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
Street Address:	NO. 369 YUZHOU SOUTH ROAD
City:	LIANYUNGANG CITY, JIANGSU PROVINCE
State/Country:	CHINA
Postal Code:	222062
Name:	MEDSHINE DISCOVERY INC.
Street Address:	ROOM 218, NO. 9, GAOXIN ROAD
Internal Address:	GAOXIN DEVELOPMENT DISTRICT
City:	NANJING, JIANGSU
State/Country:	CHINA
Postal Code:	210032
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16318523
CORRESPONDENCE DATA	
Fax Number:	(415)576-0300
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent</i>	
PATENT	

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4155760200
Email: dhill@kilpatricktownsend.com
Correspondent Name: KILPATRICK TOWNSEND & STOCKTON LLP
Address Line 1: 1100 PEACHTREE STREET
Address Line 4: ATLANTA, GEORGIA 30309

ATTORNEY DOCKET NUMBER:	093031-1122890
--------------------------------	----------------

NAME OF SUBMITTER:	DONNA HILL
---------------------------	------------

SIGNATURE:	/Donna Hill/
-------------------	--------------

DATE SIGNED:	05/13/2019
---------------------	------------

Total Attachments: 12

source=Executed-assignment#page1.tif
source=Executed-assignment#page2.tif
source=Executed-assignment#page3.tif
source=Executed-assignment#page4.tif
source=Executed-assignment#page5.tif
source=Executed-assignment#page6.tif
source=Executed-assignment#page7.tif
source=Executed-assignment#page8.tif
source=Executed-assignment#page9.tif
source=Executed-assignment#page10.tif
source=Executed-assignment#page11.tif
source=Executed-assignment#page12.tif

ASSIGNMENT
(Patent Application)

We [I], the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) or design patent application entitled

“INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR,”

the specification of which is provided with this Assignment and identified by the Attorney Docket No. above. (Serial No. 16/318,523 filed on January 17, 2019)

For one dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which we [I] acknowledge, we [I]:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., a corporation in China having a principal place of business at No. 369 Yuzhou South Rd., Lianyungang City, Jiangsu Province 222062, The People's Republic of China and MEDSHINE DISCOVERY INC., a corporation in China having a principal place of business at Room 218, No.9 Gaoxin Road, Gaoxin Development District, Nanjing, Jiangsu 210032, The People's Republic of China (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and
 - (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

- (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us [me], as well as our [my] heirs, legal representatives, and assigns.
 5. Promise and affirm that we [I] have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
 6. Authorize Kilpatrick Townsend & Stockton to insert above the application number and filing date of the above-described patent application when known.

Signed on the dates indicated beside our [my] signatures [signature].

Signature: Yuanshan YAO Date: 2009-01-25
Yuanshan YAO

ASSIGNMENT
INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR
Attorney Docket No. 093031-J122890-003800US
Page 3 of 12

Signature:  Date: 2019-03-25
Bin CHEN

ASSIGNMENT
INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR
Attorney Docket No. 093031-1122890-003800US
Page 4 of 12

Signature: Yuan CHEN Date: 2019-03-25
Yuan CHEN

ASSIGNMENT
INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR
Attorney Docket No. 093031-1122890-003800US
Page 5 of 12

Signature: Ao LI Date: 2019-03-25
Ao LI

ASSIGNMENT
INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR
Attorney Docket No. 093031-1122890-003800US
Page 6 of 12

Signature: Ran XU Date: 2019-03-25
Ran XU

ASSIGNMENT
INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR
Attorney Docket No. 093031-1122890-003800US
Page 7 of 12

Signature: Zhensheng HUANG Date: 2019-03-25
Zhensheng HUANG

ASSIGNMENT
INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR
Attorney Docket No. 093031-1122890-003800US
Page 8 of 12

Signature: Dongdong TIAN Date: 2019-03-25
Dongdong TIAN

ASSIGNMENT
INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR
Attorney Docket No. 093031-1122890-003800US
Page 9 of 12

Signature: Hongwei LI Date: 2019-03-25
Hongwei LI


ASSIGNMENT
INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR
Attorney Docket No. 093031-1122890-003800US
Page 10 of 12

Signature: Chengshuai Yang Date: 2019-03-25
Chengshuai Yang

ASSIGNMENT
INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR
Attorney Docket No. 093031-1122890-003800US
Page 11 of 12


Signature: _____

Jian LI

A handwritten signature in black ink, appearing to be 'Jian LI', written over a horizontal dotted line.

Date: 2019-03-25

ASSIGNMENT
INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR
Attorney Docket No. 093031-1122890-003800US
Page 12 of 12

Signature:  Date: 2019/2/22
Shuhui Chen

71495531V.1